CMS gives thumbs-up to PET/Alzheimer’s coverage
This article was originally published in The Gray Sheet
Executive Summary
Final decision memo aligns with draft decision to cover the scans in a practical clinical trial and for differentiating between Alzheimer's disease and fronto-temporal dementia in patients that have been evaluated for other causes of dementia and still have uncertain clinical symptoms (1"The Gray Sheet" June 24, 2004, p. 6). The national coverage decision is the first reviewed under Medicare Modernization Act requirements for a draft decision posting followed by a 30-day comment period, and implementation of a final policy within 90 days of posting a final decision memo...
You may also be interested in...
Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia
CMS' decision to provide national coverage of FDG-PET imaging for some suspected dementia patients corresponds with the Neuroimaging Work Group of the Alzheimer's Association's consensus position
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.